REPORT DIFF
Novo Nordisk A/S — what changed
3. Financial Analysis (14 changed lines)
− | Diluted EPS | $3.30 | $3.46 | $2.70 | $3.28 | $3.49 |
− | EPS Growth | 15.2% | 17.8% | -23.8% | 21.5% | 1.8% |
− | Diluted Shares (M) | 2,303 | 2,272 | 4,495 | 4,463 | 4,448 |
+ | Diluted EPS | $1.65 | $1.73 | $2.70 | $3.28 | $3.49 |
+ | EPS Growth | 15.2% | 17.8% | 52.4% | 21.5% | 1.8% |
+ | Diluted Shares (M) | 4,606 | 4,545 | 4,495 | 4,463 | 4,448 |
− | Diluted EPS | -2.0% | 5.0% | - |
+ | Diluted EPS | 23.5% | 20.7% | - |
− Net income of $15,517.8M grew just 1.4% and diluted EPS 1.8% — the first near-flat bottom line after years of double-digit compounding (net income compounded 22.6% over the prior three years). Note that the diluted share count roughly doubles between FY2022 and FY2023 — the mechanical effect of the 2023 stock split rather than issuance — so the multi-year diluted-EPS and FCF-per-share CAGRs in the
+ Net income of $15,517.8M grew just 1.4% and diluted EPS 1.8% — the first near-flat bottom line after years of double-digit compounding (net income compounded 22.6% over the prior three years). The per-share history in the tables is split-adjusted: the September 2023 2-for-1 share split is applied retroactively to the pre-split years, so the diluted-EPS and FCF-per-share series — and every multi-ye
− | Book Value / Share | $4.68 | $5.29 | $3.52 | $4.46 | $6.86 |
+ | Book Value / Share | $2.34 | $2.64 | $3.52 | $4.46 | $6.86 |
− | FCF / Share | $3.36 | $4.16 | $2.68 | $2.40 | $2.01 |
+ | FCF / Share | $1.68 | $2.08 | $2.68 | $2.40 | $2.01 |